PMID- 29164087
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220310
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 5
DP  - 2017
TI  - Plasma Brain-Derived Neurotrophic Factor Levels in Newborn Infants with Neonatal 
      Abstinence Syndrome.
PG  - 238
LID - 10.3389/fped.2017.00238 [doi]
LID - 238
AB  - BACKGROUND: Brain-derived neurotrophic factor (BDNF) is a type of growth factor 
      that promotes growth and survival of neurons. Fetal exposure to opiates can lead 
      to postnatal withdrawal syndrome, which is referred as neonatal abstinence 
      syndrome (NAS). Preclinical and clinical studies have shown an association 
      between opiates exposure and alteration in BDNF expression in the brain and serum 
      levels in adult. However, to date, there are no data available on the effects of 
      opiate exposure on BDNF levels in infant who are exposed to opiates in utero and 
      whether BDNF level may correlate with the severity of NAS. OBJECTIVE: To compare 
      plasma BDNF levels among NAS and non-NAS infants and to determine the correlation 
      of BDNF levels and the severity of NAS. METHODS: This is a prospective cohort 
      study with no intervention involved. Infants >/=35 weeks of gestation were 
      enrolled. BDNF level was measured using enzyme-linked immunosorbent assay 
      technique from blood samples drawn within 48 h of life. The severity of NAS was 
      determined by the length of hospital stay, number of medications required to 
      treat NAS. RESULTS: 67 infants were enrolled, 34 NAS and 33 non-NAS. Mean 
      gestational age did not differ between the two groups. Mean birth weight of NAS 
      infants was significantly lower than the non-NAS infants (3,070 +/- 523 vs. 
      3,340 +/- 459 g, p = 0.028). Mean BDNF level in NAS group was 252.2 +/- 91.6 ng/ml, 
      significantly higher than 211.3 +/- 66.3 ng/ml in the non-NAS group (p = 0.04). 
      There were no differences in BDNF levels between NAS infants that required one 
      medication vs. more than one medication (254 +/- 91 vs. 218 +/- 106 ng/ml, p = 0.47). 
      There was no correlation between the BDNF levels and length of hospital stay 
      (p = 0.68) among NAS infants. Overall, there were no significant correlations 
      between BDNF levels and NAS scores except at around 15 h after admission 
      (correlation 0.35, p = 0.045). CONCLUSION: Plasma BDNF level was significantly 
      increased in NAS infants during the first 48 h when compared to non-NAS infants. 
      The correlations between plasma BDNF levels and the severity of NAS warrant 
      further study. These results suggest that BDNF may play a neuromodulatory role 
      during withdrawal after in utero opiate exposure.
FAU - Subedi, Lochan
AU  - Subedi L
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Huang, Hong
AU  - Huang H
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Pant, Amrita
AU  - Pant A
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Westgate, Philip M
AU  - Westgate PM
AD  - Department of Biostatistics, College of Public Health, University of Kentucky, 
      Lexington, KY, United States.
FAU - Bada, Henrietta S
AU  - Bada HS
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Bauer, John A
AU  - Bauer JA
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Giannone, Peter J
AU  - Giannone PJ
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
FAU - Sithisarn, Thitinart
AU  - Sithisarn T
AD  - Department of Pediatrics, University of Kentucky, Lexington, KY, United States.
LA  - eng
GR  - R01 HD070792/HD/NICHD NIH HHS/United States
PT  - Journal Article
DEP - 20171103
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC5675851
OTO - NOTNLM
OT  - brain derived neurotrophic factor
OT  - effect of opiate exposure
OT  - intrauterine opiate exposure
OT  - neonatal abstinence syndrome
OT  - neurobehavioral outcome
EDAT- 2017/11/23 06:00
MHDA- 2017/11/23 06:01
PMCR- 2017/11/03
CRDT- 2017/11/23 06:00
PHST- 2017/07/31 00:00 [received]
PHST- 2017/10/20 00:00 [accepted]
PHST- 2017/11/23 06:00 [entrez]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2017/11/23 06:01 [medline]
PHST- 2017/11/03 00:00 [pmc-release]
AID - 10.3389/fped.2017.00238 [doi]
PST - epublish
SO  - Front Pediatr. 2017 Nov 3;5:238. doi: 10.3389/fped.2017.00238. eCollection 2017.